Streetinsider.com Pre-Open Movers 07/22: (HIMX) (BCRX) (NAFC) Higher; (THRX) (YHOO) (DWA) Lower (more...)

Himax Technologies, Inc. (Nasdaq: HIMX) 30.8% HIGHER; announced that it has entered into an agreement with Google Inc. (Nasdaq: GOOG) pursuant to which Google has agreed to invest in the Company's subsidiary, Himax Display Inc. ("HDI").

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) 19.9% HIGHER;announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives. The safety, tolerability, drug exposure and on-target kallikrein inhibition results of this Phase 1 trial strongly support advancing the development program into a Phase 2a study in hereditary angioedema (HAE) patients.

Nash Finch Company (Nasdaq: NAFC) 16.7% HIGHER; Spartan Stores, Inc. and Nash Finch Company announced that they have entered into a definitive merger agreement under which Spartan Stores and Nash Finch will combine in an all-stock merger valued at approximately $1.3 billion, including existing net debt at each company.

Petmed Express, Inc. (NASDAQ: PETS) 15.3% HIGHER; reported Q1 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $74.2 million versus the consensus estimate of $69.55 million.

Spartan Stores, Inc. (Nasdaq: SPTN) 14% HIGHER; Spartan Stores, Inc. and Nash Finch Company announced that they have entered into a definitive merger agreement under which Spartan Stores and Nash Finch will combine in an all-stock merger valued at approximately $1.3 billion, including existing net debt at each company.

Tremor Video, Inc. (Nasdaq: TRMR) 4% HIGHER; new Buy ratings as Wall Street launches coverage

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) 4% HIGHER; announced data from a Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIIIRx experienced reductions of up to 70 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides. In addition, patients treated with ISIS-APOCIIIRx experienced an up to 52 percent increase in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and an up to 77 percent reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles. Isis is also evaluating ISIS-APOCIIIRx in this Phase 2 study as a monotherapy in patients with severely high triglycerides and plans to report these data at the European Society of Cardiology on August 31 in Amsterdam.

Theravance Inc. (NASDAQ: THRX) 3.7% LOWER; Morgan Stanley resumed coverage with an Underweight rating and a price target of $13.00. Analyst David Friedman is cautious on the company's respiratory franchise, and he thinks peak sales of Relovair will be much lower than expected, as it appears to be "insufficiently differentiated."

Yahoo! Inc. (Nasdaq: YHOO) 3.6% LOWER; entered into an agreement to repurchase 40 million shares of Yahoo! common stock beneficially owned by Third Point LLC ("Third Point"), at a purchase price of $29.11 per share. The purchase price equals the closing price of Yahoo! common stock on July 19, 2013. Following the repurchase, Third Point will beneficially own approximately 20 million shares, representing less than 2 percent of Yahoo!'s outstanding common stock. In accordance with the Boards settlement agreement announced on May 13, 2012, each of the directors originally nominated by Third Point -- Daniel S. Loeb, Harry J. Wilson, and Michael J. Wolf -- have submitted their resignations from Yahoo!'s board of directors, effective July 31, 2013.

DreamWorks Animation (NASDAQ: DWA) 3.6% LOWER; Turbo doesn't do well.

McDonald's Corp. (NYSE: MCD) 3% LOWER; reported Q2 EPS of $1.38, $0.02 worse than the analyst estimate of $1.40. Revenue for the quarter came in at $7.08 billion versus the consensus estimate of $7.1 billion. Global comps up 1.0 percent.

Six Flags Entertainment Corp. (NYSE: SIX) 2.2% LOWER; reported Q2 EPS of $0.47, $0.06 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $451 million versus the consensus estimate of $370 million.

Juniper Networks (NYSE: JNPR) 2.2% LOWER; Jefferies downgraded from Buy to Hold with a price target of $21.25, saying risk/reward is balanced.

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks